HORSHAM, Pa., July 23, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the issuance and sale of 665,136 shares of its common stock at an average purchase price of $3.16 per share for total gros ...

HORSHAM, Penn., July 22, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the approval of its XTRAC Momentum™ 1.0 device by the Ministry of Health, Labor and Welfare of Japan. The Company initially launched the XTRAC Momentum™ in the U.S. in early 2022. The immediate commercial rollout of the device in J ...

HORSHAM, Pa., July 17, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the publication of a clinical study titled, "Advancing precision acne therapy using a photopneumatic device," in the July 11, 2024 issue of the Journal of Cosmetic and Laser Therapy. All patients experienced a visible reduction in co ...

HORSHAM, Penn., June 12, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the availability of two virtual webinars that discuss the benefits of using its XTRAC® excimer device for the treatment of psoriasis, vitiligo, and eczema and its TheraClear®X photopneumatic device for the treatment of mild to mode ...

Significant reduction in acne lesion counts at each visit compared to the baseline. ≥1 grade reduction in Investigator's Global Assessment (IGA) for two-thirds (20/30) of participants by Day 49. Visible improvements as early as after 3 treatments. Consistent enhancements in patient Acne Quality of Life and satisfaction scores across all time points. Well-tolerated treatments with no treatment-related adverse events. High treatments satisfaction with 80% of participants reported being satisfied or very satis ...

Dr. Ablon noted, "I am thrilled with the clinical study results for TheraClearX Acne System. The data clearly demonstrates TheraClear®X's efficacy and safety, providing a significant improvement for Acne patients. Noninvasive devices are always needed in the acne armamentarium!" Safe Harbor The study concluded that photopneumatic monotherapy effectively reduces acne lesions across all Fitzpatrick skin types with favorable tolerability and participant satisfaction. Customizable settings allow tailored treatm ...

HORSHAM, Penn., June 04, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its participation in two dermatology conferences in the month of June. On June 1, STRATA has participated in the inaugural Schweiger Symposium at the Jacob Javits Center in New York City. The Symposium brought together dermatology ...

We come in and we grandfather an existing business and what we need to do is provide them the technology, the training, the support, the reimbursement support and so on. But it gives us a head start on taking a new account and starting from scratch. Operator STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q1 2024 Results Conference Call May 2, 2024 4:30 PM ET Company Participants Dolev Rafaeli - Chief Executive Officer Chris Lesovitz - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) | Delaware | 13-3986004 | | --- | --- | | (State or Other Jurisdiction of incorporati ...

Exhibit 99.1 STRATA Skin Sciences Reports First Quarter 2024 Financial Results and Provides a Corporate Update HORSHAM, Penn., May 15, 2024 – STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights • Revenue in the ...